The U.S. Supreme Court has refused to take up Girardi Keese’s fight against turning over more than $10 million in proceeds from a 2012 settlement to the lead attorneys in multidistrict litigation involving the diabetes drug Avandia.
Plaintiffs firm Girardi Keese filed more than 4,000 cases against GlaxoSmithKline PLC alleging that Avandia increased the plaintiffs’ risk of heart failure. Most were in California state court, but 25 were in the multidistrict litigation, which is pending in the U.S. District Court for the Eastern District of Pennsylvania.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
